CG Invites Calls Extraordinary General Meeting: 507,000 Stock Options and Director Elections Aim to Strengthen Governance

An extraordinary general meeting will be held on June 29, 2026, with agenda including director elections, partial amendment of articles, and stock option grants.
Stock options for 507,000 common shares will be granted to 86 employees via new share issuance, representing a modest dilution of approximately 0.66% of outstanding shares. The exercise price will be set at fair value determined prior to the meeting, with a two-year vesting period and five-year exercise window.
New director candidates include Kim Yujeong, CEO of Pungjeon Pharmaceutical, as inside director; Shin Yonggyu, former Blackstone Korea head, as inside director; and Han Taeil, attorney, as outside director. Given low board attendance rates of current directors, these appointments aim to enhance governance expertise and independence.
Article amendments add business purposes for management efficiency and introduce a provision for acting chairman. A related-party transaction of 37 million KRW with Invitos Biocore, a major shareholder affiliate, is disclosed.
No share buyback or cancellation is announced. The limited dilution from stock options is unlikely to significantly impact shareholder value.
[AI Summary]CG Invites seeks to bolster management stability through a modest stock option grant and professional director appointments. While low board attendance and related-party dealings warrant monitoring, the overall capital impact is minimal, posing no major threat to shareholder value.